Pharmacokinetics of teicoplanin in the elderly

Abstract

The pharmacokinetic profile of teicoplanin was studied in 12 elderly patients with a moderate degree of renal impairment (mean creatinine clearance, 51.3 ml/h/kg before treatment), after a single 6 mg/kg iv dose. Pharmacokinetic parameters were estimated both by a three-compartment open pharmacokinetic model and by non-compartmental analysis; peak plasma levels, 15 min after administration, averaged 45 mg/l. The half-lives of two distributive phases were 0.39 and 7.3 h, respectively. The elimination half-life averaged 107 h, with similar estimates obtained from the three-compartment analysis and from urinary data. The volume of distribution from the central compartment was 0.09 l/kg while the volumes of distribution at steady state and during the elimination phase were 1.3 and 1.6 l/kg, respectively. The total teicoplanin clearance averaged 10.6 ml/h/kg, with renal clearance accounting for about 40% of the total. There was a linear correlation between teicoplanin total or renal clearance and endogenous creatinine clearance. The average total recovery of teicoplanin in urine over eight days was 28%. There were no local or systemic adverse reactions to teicoplanin.

Efficacy of teicoplanin for the prevention of surgical site infections after total hip or knee arthroplasty: a prospective, open-label study

“…Based on the expected admission rate for each participating centre for 18 months and their bed occupancies, distributions of regimens through the three departments was designed as follows: all patients admitted and operated on in the 3rd Department of Orthopaedics were administered surgical chemoprophylaxis of one dose of teicoplanin (Targocid; VIANEX, Athens, Greece) upon induction of anaesthesia. The selected dose was 10 mg/kg as suggested elsewhere [10][11][12]. The dose was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 min and it was diluted in 5% glucose solution to a final volume of 50 mL.…”

Variability in Teicoplanin Protein Binding and Its Prediction Using Serum Albumin Concentrations

“…The pharmacokinetics of teicoplanin has been studied and is known to vary under differing conditions, including renal impairment 12 , renal support therapies 13 , elderly 14 , and neutropenia 15 . MRSA infections may occur frequently on such immunocompromised hosts.…”

The prevalence of meticillin-resistant Staphylococcus aureus in long-term care facilities: is there a need for tailored glycopeptide prophylaxis?

“…It has excellent tissue penetration and a particularly long half-life (70-100 hours), allowing single-dose administration. It is also proved to reduce the rate of MRSA SSI following orthopaedic surgery ( Soriano et al, 2006 ), and it can be used safely in elderly patients and those with renal impairment, without any local or systemic complications ( Rosina et al, 1988 ).…”